IGI Laboratories sees FY15 revenue $35M-$45M, consensus $38.69M Expects sequential improvement in quarter over quarter in total revenue for the remainder of the year. Sees FY15 gross margin 43%-50% due to sequential improvement in gross margin quarter over quarter for the remainder of the year. The company continues to expect to submit an additional four ANDAs before June 30, 2015, and intends to have submitted a total of 20 ANDAs by the end of 2015. In order to complete all of the development work required for the 2015 filings, the company expects to spend between $13M and $14.5M in research and development by the end of 2015. As a result of the expected sequential increase in total revenue in the third and fourth quarter of 2015, the company intends to return to a break-even operating margin in the fourth quarter of 2015.